In contrast, significant downregulation of CASC9 was found in the pan-cancer TCGA data in renal cell carcinoma (KIRC, KICH, KIRP), thyroid cancer (THCA), and prostate cancer (PRAD) (Fig. 3). Here, CASC9 is linked to hereditary clear cell renal cell carcinoma.